Products For The Hong Kong Market

Xtandi® (Prostate cancer treatment)

Xtandi® is a treatment that decreases cell growth and induces apoptosis by inhibiting multiple steps in the androgen receptor signaling pathway, an important pathway in the growth of prostate cancer. Xtandi® was first launched in 2012 in the United States with an indication for the treatment patients with metastatic castration-resistant prostate cancer (CRPC) whose disease has progressed on or after chemotherapy. Subsequently, it has also been approved for metastatic chemo-naïve CRPC patients. Xtandi® is sold in approximately 70 countries/areas.

Eligard® (Prostate cancer treatment)

Eligard® is a luteinizing hormone-releasing hormone (LHRH) agonist for the treatment of prostate cancer that is marketed by Astellas in approximately 50 countries throughout the EMEA and Asia & Oceania regions.

Betmiga® (OAB treatment)

Mirabegron is a beta-3 adrenergic agonist indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency. Mirabegron is the only OAB treatment option in its class that targets the β3 pathway. Mirabegron is sold in approximately 50 countries worldwide under the brand name of Betanis® in Japan, Myrbetriq® in the U.S. and Canada, Myrbetric® in Latin America, and Betmiga® in EU, MENASA, Russia/CIS, and Asia & Oceania.

Vesicare® (OAB treatment)

Solifenacin is a muscarinic antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency. Solifenacin binds to certain natural body proteins (receptors) which help the bladder muscle to contract. This can help control the symptoms of frequent urges and leaks. Solifenacin is now marketed in approximately 80 countries worldwide.

Harnal® (Treatment for functional symptoms associated with benign prostatic hyperplasia (BPH))

Tamsulosin is indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH). Tamsulosin is an α1 blocking agent with great selectivity for prostatic and urethral smooth muscle. It is marketed in approximately 100 countries worldwide.

Prograf® and Advagraf® (Immunosuppressant)

This drug is an immunosuppressant used to suppress organ transplant rejection. It is sold in approximately 100 countries and regions and has made a significant global contribution in the field of transplantation.

Mycamine® (Candin-type antifungal agent)

This drug is a candin-type antifungal agent used for the treatment of fungal infections. It operates by inhibiting synthesis of the fungus cell wall. It is marketed in about 60 countries around the world.

Feburic® (Selective inhibitor of xanthine oxidase)

Feburic® is a potent nonpurine selective inhibitor of xanthine oxidase used in the treatment of chronic gout.  It inhibits xanthine oxidase, thus reducing production of uric acid in the body. 

Disclaimer

The information contained in this section is intended for healthcare professionals only. Are you a healthcare professional?

NO